Profibrotic cells that develop upon injury generate permanent scar tissue and impair organ recovery, though their origin and fate are unclear. Here we show that transient expression of ADAM12 (a disintegrin and metalloprotease 12) identifies a distinct proinflammatory subset of platelet-derived growth factor receptor-a-positive stromal cells that are activated upon acute injury in the muscle and dermis. By inducible genetic fate mapping, we demonstrate in vivo that injury-induced ADAM12 + cells are specific progenitors of a major fraction of collagen-overproducing cells generated during scarring, which are progressively eliminated during healing. Genetic ablation of ADAM12 + cells, or knockdown of ADAM12, is sufficient to limit generation of profibrotic cells and interstitial collagen accumulation. ADAM12 + cells induced upon injury are developmentally distinct from muscle and skin lineage cells and are derived from fetal ADAM12 + cells programmed during vascular wall development. Thus, our data identify injury-activated profibrotic progenitors residing in the perivascular space that can be targeted through ADAM12 to limit tissue scarring. 
Skeletal muscle and skin have exceptional regenerative capacity and can undergo many rounds of repair in response to injury 1, 2 . Although parenchymal regeneration is ensured by tissue stem cells, efficient tissue repair requires activation of the surrounding stromal micro environment, mainly αsmooth muscle actin-positive (αSMA + ) myofibroblasts, to produce growth and survival factors, proinflam matory chemokines and components of the extracellular matrix, such as collagens. Inappropriate activation of the stromal compartment, however, leads to persistence of αSMA + collagenoverproducing cells (also called profibrotic cells), extracellular matrix accumulation and overgrowth of fibrous or adipogenic tissue, thereby compromis ing organ recovery and impairing function 3 . In the skeletal muscle, overgrowth of fibrous tissue has been suggested to originate from muscle stem cells exposed to environmental modifications associated with aging or injury 4, 5 . In addition, resident plateletderived growth factor receptorα-positive (PDGFRα + ) mesenchymal cells distinct from muscle stem cells proliferate early upon muscle damage to pro mote tissue regeneration and show fibrogenicadipogenic bipotential in vitro 6, 7 . Accordingly, chronic activation of PDGFRα leads to wide spread organ fibrosis in mice 8 .
Myofibroblasts are a functionally heterogeneous population of cells and, at least in vitro, can be generated from several cell types, including circulating bone marrow-derived CD45 + CD34 + fibrocytes, fibroblasts, epithelial cells, mesenchymal stem cells, perivascular cells and nerveassociated cells [9] [10] [11] [12] [13] . Genetic cellfate mapping would allow the identification of relevant precursors to profibrotic cells in vivo, in the context of acute muscle and dermis injury, with minimal perturbation of the biological system being investigated 14 . However, such genetic approaches require specific markers that have yet to be reported for profibrotic cells.
ADAM12 is a membraneanchored metalloprotease that is implicated in the signaling of epidermal growth factor, insulinlike growth factor and transforming growth factorβ (TGFβ) [15] [16] [17] . ADAM12 is transiently expressed during embryonic morphogenesis of skeletal muscles and visceral organs 18 and is reexpressed in several human diseases with a fibrotic component, such as liver and muscle injuries, scleroderma and desmoplastic tumors including aggressive fibromatosis [19] [20] [21] [22] [23] . Such a restricted and specific expression pattern prompted us to investigate the identity and role of ADAM12 + cells during injury. Using models of acute injury in the muscle and the dermis, we demonstrate here that ADAM12 + cells are programmed during vascular wall development and are reinduced by injury as a distinct subset of PDGFRα + perivascular progenitors with a specific profibrotic fate and function. Accordingly, such cells can be specifically targeted to limit the generation of profi brotic cells and collagen accumulation during scarring.
RESULTS

Injury induces the development of ADAM12 + PDGFR-a + cells
To label ADAM12 + cells, we generated transgenic mice, termed M12CIG, expressing GFP and Cre recombinase under control of the Adam12 locus on a bacterial artificial chromosome (BAC; Fig. 1a) . We have shown earlier that acute tissue injury induced by complete Freund's adjuvant (CFA) injection into the ear dermis induces, within days, a massive generation of proinflammatory gp38 + myofibroblasts expressing low to medium levels of αSMA (αSMA low/med ) and genes essential for leucocyte recruitment and survival 24 . In M12 CIG mice, we detected Adam12expressing GFP + cells in a subset of CFAinduced gp38 + stromal cells that developed around muscle fibers close to the ear cartilage (Fig. 1a) and infiltrated the dermis during the following week (Supplementary Fig. 1a) . A similar process was observed in skeletal muscle after cardiotoxininduced injury (Fig. 1a) , a model for acute muscle injury and regeneration 25 . At 4 d after injury, ADAM12 + cells represented <1% of total nonhematopoietic (CD45 − ), nonendothelial (CD31 − ) stromal cells (Fig. 1b) . Gp38 + stro mal cells expanded markedly during the first few days after injury and then decreased progressively over 1 month (Fig. 1c) . Other stromal populations, such as PDGFRα + cells and PDGFRβ + cells, expanded similarly during the first week and partially overlapped with gp38 + cells (Supplementary Fig. 1b) . The highest number of ADAM12 + cells occurred 4 d after injury (representing 4.6% of total gp38 + cells in the muscle); however, their numbers decreased rapidly thereafter in contrast to gp38 + stromal cells (Fig. 1c) . A similar kinetic profile has been reported for muscleresident PDGFRα + Sca1 + mesenchymal cells proliferating upon muscle damage; this cell population shows fibrogenicadipogenic bipotential, with roles in tissue regeneration and ectopic fat formation 6, 7 . Accordingly, injuryinduced ADAM12 + cells all expressed PDGFRα and Sca1 ( Fig. 1c and Supplementary  Fig. 1c,d ), although they represented only a minor fraction of total PDGFRα + mesenchymal cells.
At 4 d after CFA or cardiotoxininduced injury, ADAM12 + cells expressed transcripts for nerve growth factor receptor (Ngfr, also known as p75NTR or p75), neural cell adhesion molecule 1 (Ncam1) and glial fibrillary acidic protein (Gfap; Fig. 1d ). This phenotype is reminiscent of Schwann cells dedifferentiating upon nerve injury 26 . Such a phenotype has also been reported for particular stromal cell populations, such as hepatic stellate cells, which are the main collagen expressing cells upon liver injury 27 . Notably, p75 is required for the differentiation of stellate cells into αSMA + collagenproducing myofibroblasts 28 . In the first 2 weeks after injury, similar to our ear lier findings on gp38 + cells in inflamed tissues 24 , ADAM12 + cells expressed proinflammatory chemokines and cytokines (Fig. 1d) . These cells also expressed transcripts for connective tissue growth factor (Ctgf) and Tgfb1, both of which are involved in the differentia tion of myofibroblasts and Pdgfrb, the latter of which has an essential role in pericyte recruitment 29 .
The potential of injuryinduced ADAM12 + to differentiate into αSMA + myofibroblasts was confirmed in vitro. ADAM12 + stromal cells isolated 4 d after injury were mostly spherical and poorly adher ent. When grown in TGFβ-supplemented medium, the majority of cells (>85%) differentiated into adherent αSMA + myofibroblasts with prominent stress fibers (Fig. 1e) Fig. 1f ). Together, these data indicate that a subset of gp38 + PDGFR α + Sca1 + cells, transiently expressing ADAM12 upon injury, preferen tially differentiates into proinflammatory myofibroblasts.
Injury-induced myofibroblasts are progeny of ADAM12 + cells ADAM12 + cells were most prominent during the first week after injury and cell numbers declined thereafter (Fig. 1c) . To determine the fate of ADAM12 + cells in vivo, we mapped their cellular progeny by crossing M12CIG mice to Credependent Rosa26 floxSTOPRFP reporter mice 30 (M12cre/RFP, Fig. 2a) . In such mice, all the prog eny of ADAM12 + cells was permanently labeled with RFP, whereas ADAM12 + cells expressed both GFP and RFP. RFP + cells, present before injury albeit at low numbers, markedly expanded upon injury (Fig. 2b) to represent a major fraction of gp38 + and PDGFRα + stromal cells within a few days to 2 weeks after injury ( Fig. 2c and Supplementary Fig. 2a , respectively) and then progressively decreased in number as the tissue healed. The expansion of RFP + cells followed extensive proliferation of ADAM12 + cells in the first days after injury, whereas proliferation of RFP + GFP − cells was less marked but still substantial 15 d after injury (Fig. 2d) . At 20 d after injury, 60-70% of αSMA + myofibroblasts were progeny of ADAM12 + cells (Fig. 2e) . In contrast, no muscle fibers or skin epi dermal cells expressed RFP (Supplementary Fig. 2b ), indicating that ADAM12 + cells are developmentally distinct from muscle and skin tissue stem cells activated upon injury. Finally, a parabiosis experi ment, in which an M12CIG mouse and a wildtype partner were surgically sutured together, confirmed that ADAM12 + cells were resident and not recruited from the bloodstream (Fig. 2f ) . Together, these results indicate that a majority of gp38 + , PDGFRα + and αSMA + myofibroblasts generated in vivo upon muscle and dermis acute injury is derived from tissueresident ADAM12 + cells.
ADAM12 + profibrotic cells are induced de novo by injury
As ADAM12 is expressed during ontogeny 18 , and cells derived from ADAM12 + progenitors were detected before injury (Fig. 2b , time 0), we investigated whether myofibroblasts were generated from ADAM12 + cells induced de novo by injury. To that end, we carried out an inducible, tetracycline transactivator-based cell fate mapping experiment. We generated M12tTA/LC1/YFP mice that express tetra cycline transactivator under control of the Adam12 locus on a BAC (M12tTA TG ), Cre under control of the tetracycline transactivator (LC1; ref. 31 ) and the conditional reporter Rosa26 floxSTOPYFP locus 32 ( Fig. 3a) . In these tripletransgenic mice, YFP labeling of the prog eny of ADAM12 + cells is controlled in time by the administration of doxycycline, which blocks the tetracycline transactivator-mediated labeling cascade, allowing for the distinct fate mapping of fetal and adult injuryinduced ADAM12 + cells (Fig. 3b) .
First, we administered doxycycline continuously from concep tion until shortly before tissue injury (embryonic day 0 to postnatal day 23, E0-P23) to map the fate of adult ADAM12 + cells induced de novo by injury. In that setting, and 10 d after injury, 50% (in the dermis) and 60% (in the tibialis anterior muscle) of the injured areas were infiltrated with YFP + cells (Fig. 3c , doxycyline E0-P23) with a CD45 − gp38 + PDGFRα med/high phenotype ( Fig. 3d) , demonstrat ing that a major fraction of the injuryinduced stroma is generated from ADAM12 + cells induced de novo by injury. In these conditions, up to 53% of total gp38 + cells in the whole tibialis anterior muscle were progeny of ADAM12 + cells at 20 d after injury; this percentage npg gradually decreased as the tissue healed (Fig. 3e) . Most YFP + cells expressed αSMA low/med , consistent with progressive differentiation into αSMA + myofibroblasts (Fig. 3f ) . Furthermore, most progeny of injuryinduced ADAM12 + cells colocalized with interstitial colla gen deposits, both during muscle regeneration and when healing was mostly achieved at 40 d after injury (Fig. 3g) , showing that de novoinduced ADAM12 + cells generated a subset of stromal cells targeted to fibrotic regions of the tissue. The presence of a subset of αSMA + Col1A + YFP − cells (20-30% at 10 d after injury, Supplementary Fig. 3a) indicated that the effi ciency of the tetracycline transactivator-based labeling system is not 100%, or that subsets of myofibroblasts arise from distinct origins and potentially carry different functions. At 40 d after injury, inter stitial mesenchymal cells in regenerated normal muscle tissue were not progeny of ADAM12 + cells (Supplementary Fig. 3b) .
Next, we administered doxycyline continuously from birth (P1-P50) to map the fate of fetal ADAM12 + cells. In the ear dermis, the progeny of fetal ADAM12 + cells was already substantial before injury and further expanded to include most stromal cells after injury (Fig. 3c, P1-P50 ), indicating that ADAM12 is expressed during ontogeny by early mesenchymal progenitors (such as cranial neural crest cells, which generate all mesenchyme of the head 33 ). In skel etal muscle, the progeny of fetal ADAM12 + cells, which was limited before injury, expanded to 40% of injured areas (Fig. 3c, P1-P50 ).
In both ear dermis and muscle, the progeny of fetal ADAM12 + cells included αSMA + cells (Fig. 3f) and other cell types (such as nerves, Supplementary Fig. 3c ), in contrast to the progeny of de novoinduced ADAM12 + cells. Thus, the progeny of fetal ADAM12 + cells included both fibrogenic and nonfibrogenic lineages, but only cells of the fibrogenic lineage reexpressed ADAM12 upon acute injury (schematic diagram, Supplementary Fig. 4) . (Fig. 4a) To formally demonstrate that ADAM12 + cells and their progeny have a causal role in tissue fibrosis during acute injury, we injected M12tTA/LC1/YFP mice, which also express the human diphthe ria toxin receptor under control of the Adam12 locus (Fig. 3a) , with diphtheria toxin subunit A (DTA) to induce the ablation of ADAM12 + cells. As we expected, injection of DTA induced a marked reduction of the progeny of ADAM12 + cells (YFP + cells) (Fig. 4b) and of αSMA + stromal cells (Supplementary Fig. 5) . Furthermore, consistent with the proinflammatory nature of ADAM12 + cells (Fig. 1d) , leucocyte infiltration decreased upon DTA treatment (Fig. 4c) . Because of the loss of ADAM12 + cells and their progeny, interstitial collagen was significantly reduced in injured tissues (Fig. 4d) .
Ablation of injury-induced ADAM12 + cells decreases fibrosis
Next, to test whether ADAM12 itself has a role in fibrosis, we injected injured muscle of M12CIG mice with siRNA directed against Adam12. At 3 weeks after injury, interstitial collagen within injured muscles was significantly reduced in treated mice (Fig. 4e) , as was the expression of transcripts for stromal growth factors Ctgf and Fgf1. In contrast, growth factors essential for muscle regenera tion such as Igf1 and Igf2 were increased when Adam12 was silenced (Fig. 4f) . As TGFβ has a central role in wound healing and fibrosis by stimulating expression of collagens 34 , we assessed whether ADAM12 might be involved in this process. Consistent with a role of ADAM12 in TGFβ signaling, forced expression of Adam12 in mouse fibroblastic cells in vitro increased Col1a1 expression in response to TGFβ, and silencing of endogenous Adam12 decreased Col1a1 expression upon TGFβ stimulation (Supplementary Fig. 6a,b) . Notably, Adam12 itself is rapidly, although transiently, induced by TGFβ in vitro (Supplementary Fig. 6c ).
Injury reactivates ADAM12 + cells in nerves and vascular wall
To clarify the identity of fetal and adult ADAM12 + progenitors, we mapped ADAM12 expression from ontogeny until before injury. We detected ADAM12 expression in p75 + neural crest cells (NCCs) at the outer border of the neural tube, starting at E9.5, when NCCs undergo an epithelialtomesenchymal transition and delaminate from the neural tube (Fig. 5a) . NCCs subsequently migrate and give rise to multiple neural and nonneural cell types, including cells of the peripheral nervous system and craniofacial mesenchyme 35 . ADAM12 was downregulated in NCCs after delamination and reexpressed at E12.5 in NCCderived p75 + Schwann cell precursors (SCPs), as defined by the lack of detectable expression of the Schwann cell marker S100 calciumbinding proteinβ (S100) and close association with PGP9.5 + axons 36 ( Fig. 5a and Supplementary Fig. 7a ). These find ings are in accordance with earlier micro array data showing highest expression of ADAM12 in NCCs at E9.5 and in SCPs at E12. 5 (ref. 37) . From E10 to E14, ADAM12 was also expressed in p75 + NCCs that migrated to the gut to generate the enteric nervous system (Supplementary Fig. 7a ).
In addition, at about E12.5, a population of ADAM12 + PDGFRβ + p75 − αSMA − CD31 − pax7 − mesenchymal cells was detected surrounding CD31 + endothelium in close proximity to somites ( Fig. 5a and Supplementary Fig. 7a ). As PDGFRβ-mediated signaling induces a pericyte fate in undifferentiated mesenchymal cells recruited to stabilize nascent vessels 29 , these data suggest that fetal ADAM12 + mesenchymal cells include PDGFRβ + pericyte pro genitors. During postnatal growth (before weaning age), ADAM12 was transiently reexpressed in nonmyelinating S100 + Schwann cells capping the axon terminals of the skeletal neuromuscular junc tion (NMJ), also called terminal Schwann cells (Fig. 5b) , and in PDGFRβ + perivascular cells, in both skeletal muscle and dermis ( Fig. 5b and Supplementary Fig. 7b ; the NMJ were visualized by staining with αbungarotoxin (αBgtx), which binds the nicotinic acetylcholine receptors at the NMJ). Together, these results show that ADAM12 is transiently expressed in distinct subsets of NCCderived cells as well as in mesenchymal cells in close proximity to vessels, during nerve and vascular wall development respectively. Their progeny in adult muscle and dermis therefore includes nerves and glial cells on one hand (as described for NCCs 33 ; Supplementary Fig. 3c ) and mesenchymal perivas cular cells on the other (Supplementary Fig. 8a ), which might generate myofibroblasts upon injury through adult ADAM12 + pro genitor cells. We thus characterized adult ADAM12 + cells induced within hours of injury. Reminiscent of ADAM12 expression pattern during postnatal growth, ADAM12 was first reexpressed in S100 + terminal Schwann cells capping the neuromuscular junctions and in PDGFRβ + perivascular cells of injured regions (Fig. 5c) . At 2-3 d after injury, ADAM12 + p75 +/low S100 − stromal cells not associated with the neuromuscular junction or blood vessels gradually infiltrated the interstitial stroma of injured regions (Fig. 5c) . These results indicate that tissue injury reactivates ADAM12 + cells programmed during nerve and vascular wall development.
Perivascular ADAM12 + cells are profibrotic progenitors
We found ADAM12 + cells among NCCderived Schwann cells and perivascular cells. As both cells of the NCC lineage and perivas cular cells have the potential to generate myofibroblasts 11, 12, 38 , we mapped the fate of Wnt1 + cells, as Wnt1 is expressed by NCCs 39 but not by perivascular cells. In Wnt1Cre mice (expressing Cre under the control of the Wnt1 promoter) crossed to Rosa26 floxSTOPYFP mice, nerves and S100 + Schwann cells (including terminal Schwann cells) in adult muscle and dermis were YFP + , and so were progeny of Wnt1 + cells (Supplementary Fig. 8b ). In addition, myofibroblasts developing upon ear injury expressed YFP, as mesenchyme of the head derives from NCCs 35 (Fig. 6a) . However, in contrast to the progeny of ADAM12 + cells (RFP + cells in Fig. 2b) , no S100 − stromal progeny of Wnt1 + cells was found upon muscle injury (Fig. 6a) , demonstrating that ADAM12 + profibrotic progenitors developing in cardiotoxininjured tibialis anterior muscles are not derived from the NCC lineage and ADAM12 + Schwann cells, but rather from perivas cular ADAM12 + cells. Consistent with this hypothesis, ADAM12 + cells expressed PDGFRβ and NG2, which are also expressed by pericytes (Fig. 6b,c) , as well as CD29, CD44 (Fig. 6b) , PDGFRα and Sca1 (Fig. 1c and  Supplementary Fig. 1c) , markers commonly used to identify multi potent mesenchymal progenitor cells in mice 40, 41 . However, con firming our in vitro results (Fig. 1e) , the progeny of ADAM12 + cells induced in vivo upon injury was restricted to profibrotic cells and did not include other mesenchymal derivatives such as adipo cytes, even in conditions favoring adipocyte differentiation in vivo (Supplementary Fig. 8c ). ADAM12 + cells induced upon injury were not embedded in the vascular basement membrane (the location of pericytes at steady state), in contrast to ADAM12 + cells during post natal growth (Fig. 6c) . These data indicate that ADAM12 expression identifies a profibrotic subset of mesenchymal progenitors within the perivascular space.
DISCUSSION
We found by inducible fate mapping in vivo that a majority of profi brotic cells developing upon acute muscle and dermis injury are gen erated from a distinct subset of PDGFRα + proinflammatory stromal cells that are identified by transient expression of ADAM12 upon injury. Accordingly, genetic ablation of ADAM12 + cells decreased tissue fibrosis during scarring. We further found that the profibrotic fate of ADAM12 + cells is irreversible, as interstitial mesenchymal cells repopulating the healed tissue were not derived from ADAM12 + cells. The progeny of ADAM12 + cells was gradually eliminated as the tissue recovered, indicating that healing is associated with elimination of collagenoverproducing cells, rather than reversion to a normal, more quiescent mesenchymal phenotype. This is reminiscent of observa tions in the liver, in which resolution of fibrosis is associated with apoptosis of hepatic stellate cells, the primary collagenproducing cells in the liver 42 . Consistent with the proinflammatory nature of ADAM12 + profibrotic progenitors, inflammation generally precedes and contributes to the development of fibrotic tissue, even though accumulation of fibrotic cells often outlasts inflammation 3 .
On the basis of in vitro differentiation assays, muscle stem cells have been suggested to have an alternative mesenchymal fate and generate fibrogenic cells 4, 5 . Our in vivo lineage tracing data show that ADAM12 + profibrotic progenitors do not contribute to parenchymal regeneration, indicating that they are distinct from muscle and skin stem cells. A detailed analysis shows that injuryinduced ADAM12 + cells include terminal Schwann cells capping the neuromuscular junc tion and PDGFRβ + perivascular cells, two cell types endowed with high plasticity and roles in repair mechanisms of peripheral nerves and blood vessels, respectively 29, 43 . We further demonstrate that ADAM12 + cells of the mesenchymal lineage, but not of the Schwann cell lineage, are profibrotic progenitors in acute injured skeletal muscle. This finding is in agreement with recent reports showing that the perivascular niche of multiple organs contains pluripotent mesenchymal progenitors, which are suggested to be pericytes 11, 44 . However, the cellular progeny of ADAM12 + cells induced de novo by acute injury in the cardiotoxin and CFA models is restricted to profibrotic cells and does not include other mesenchymal derivatives such as adipocytes, suggesting that distinct subsets of mesenchymal progenitors, or progenitors at different stages of differentiation, are present in adult perivascular niches. In agreement with our findings, PDGFRβ signaling opposes adipocyte differentiation in pericytes while activating immune genes 45 . In contrast to ADAM12 + cells during postnatal growth, injuryinduced ADAM12 + cells are not embedded within the vascular basement membrane, suggesting that they are activated pericytes detaching upon injury or mesenchymal cells in close proximity to vessels. The expression of pericyte mark ers such as NG2 and PDGFRβ would favor the first hypothesis. The detachment of pericytes from endothelium has been reported dur ing vascular remodeling occurring in chronic pathologies, such as tumorigenesis, diabetic retinopathy and kidney disease 46, 47 . These results are consistent with recent work in kidney fibrosis and spinal cord injury showing that subsets of pericytes are the major source of myofibroblasts and scar tissue 48, 49 .
We further found that the Adam12 molecule has a role in tissue fibrosis. Notably, transcripts for growth factors with essential roles in muscle regeneration, such as Igf1 and Igf2, were upregulated when Adam12 was silenced in vivo during injury, suggesting that target ing Adam12 alters stromal growth but favors tissue regeneration. These results are consistent with a report showing that transgenic npg overexpression of Adam12 under control of the muscle creatine kinase promoter both aggravates fibrosis and decreases muscle regeneration after injury, a phenotype further aggravated in the dystrophic back ground of mdx (Xlinked muscular dystrophy) mice 50 . ADAMs comprise several different protein modules 51 , including a catalytic domain, and disintegrinlike cysteinerich domains which have been implicated in cellcell interactions. Potential mechanisms underlying the profibrotic role of ADAM12 could therefore depend on the proteolytic release of membrane proteins (known substrates of ADAM12 include EGFR ligands 15 ) or extracellular matrix proteins, or on cellcell or cellmatrix interactions via its disintegrin domain. ADAM12 also enhances TGFβ-induced transcriptional responses by modulating TGFβ receptor trafficking 17 , consistent with our data showing that ADAM12 potentiates TGFβ-mediated type I collagen synthesis in fibroblastic cells. As Adam12 is rapidly, though tran siently, induced by TGFβ in vitro (our data and refs. 19, 52) , this sug gests the hypothesis that ADAM12 has a role in the positive feedback loop of TGFβ signaling. Nevertheless, further studies are required to determine whether this mechanism is relevant in vivo during injury. It also remains to be assessed whether ADAM12 has a direct role in the fate choice leading to the generation of αSMA + myofibroblasts rather than adipocytes.
Increasing evidence suggests that mesenchymal progenitors resid ing in adult organs have multiple developmental origins. Accordingly, an initial transient wave of mesenchymal stem cells in the postnatal bone derives from the neuroepithelial and neural crest cells 53 , whereas all mesenchymal cells of the head derive from the cranial neural crest 54 . Here we show that fetal ADAM12 + cells programmed during vascular wall development contribute to the generation of mesen chymal perivascular cells in the adult skeletal muscle. We propose that reactivation of ADAM12 + cells upon injury recapitulates an ontogenic program aimed at restoring vascular integrity, which, in the context of tissue damage and inflammation, leads to an inap propriate fibrotic outcome. The association of microvascular dam age, inflammation and fibrosis characterizes several chronic human diseases including scleroderma (systemic sclerosis), a chronic con nective tissue disease inducing extensive fibrosis of the skin and internal organs. Notably, ADAM12 is overexpressed in fibroblasts isolated from patients with scleroderma 21 . Future studies manipulat ing ADAM12 + cells in vivo are needed to assess whether persistence of such cells in scleroderma and other chronic fibrotic diseases, such as liver fibrosis and aggressive fibromatosis 19, 21, 22 , has a causal role in the continuous generation of collagenoverproducing cells and fibrosis. Our work emphasizes that elimination versus persistence of functionally distinct subsets of mesenchymal cells might be key to restoring a healthy balance in extracellular matrix production during scarring, with implications for fibrotic diseases. As ADAM12 + cells are rare in adult noninjured organs, we suggest that targeting injury induced ADAM12 + cells, or inhibiting ADAM12, might represent a new therapeutic approach to specifically limit the generation of collagenoverproducing cells.
METHODS
Methods and any associated references are available in the online version of the paper.
